Pharmaceuticals
Pfizer is unnamed bidder for Swedish rare disease firm Orphan Biovitrum
02 May 2015
Pfizer’s interest in rare diseases first became evident in December 2009, when the company licensed the worldwide rights to taliglucerase alfa, a product that treats the genetic disorder Gaucher disease
Biocon Q4 net profit surges 78% to Rs202 cr
30 Apr 2015
Perrigo rejects Mylan’s latest $34.10 bn bid
30 Apr 2015
The rejection from Perrigo comes as Mylan fends off an unsolicited $40-billion takeover bid from Israeli generic drug giant Teva Pharmaceuticals
Mylan raises bid for Perrigo Co to $34.10 bn
29 Apr 2015
As a result of the increased offer, Mylan will own approximately 60.7 per cent of the merged company, while the remaining 39.3 per cent will be held by Perrigo
.webp)
